Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma

Area of Science:

• Oncology
• Cancer Research
• Medical Therapeutics

Background:

• NUT carcinoma (NC) is an aggressive, underdiagnosed cancer.
• Optimal chemotherapy regimens for NC remain unknown.
• Current expert recommendations for NC chemotherapy are based on limited case reports.

Purpose of the Study:

• To evaluate the efficacy of platinum- and ifosfamide-based chemotherapy in patients with NUT carcinoma.
• To compare progression-free survival (PFS) and overall survival (OS) between different chemotherapy regimens.
• To assess objective response rates (ORR) for various chemotherapy treatments in NC.

Main Methods:

• A worldwide registry of pathologically confirmed NC patients with known survival outcomes was utilized.
• Data from 118 NC patients who received platinum or ifosfamide-based chemotherapy were analyzed.
• Descriptive statistical methods were employed to summarize patient outcomes and treatment responses.

Main Results:

• Ifosfamide-based chemotherapy demonstrated a nominally higher PFS and a numerically higher ORR compared to platinum-based chemotherapy.
• Despite higher ORR with ifosfamide (75% vs 31%), no significant difference in PFS or OS was observed between the two regimens.
• The 3-year OS for the entire cohort was 19%, with long-term survivors predominantly having nonmetastatic and operable disease.

Conclusions:

• Ifosfamide-based chemotherapy may offer a higher response rate in NUT carcinoma, but its durability and impact on overall survival are limited.
• The overall 3-year survival rate for NUT carcinoma remains poor at 19%.
• There is an urgent unmet need for the development of more effective therapies for patients with NUT carcinoma.